4D Molecular Therapeutics, Inc. operates as a clinical stage biotherapeutics company, which engages in the design, development, and commercialization of transformative gene therapeutic products for serious unmet medical conditions. The company is headquartered in Emeryville, California and currently employs 137 full-time employees. The company went IPO on 2020-12-11. The firm is developing a diverse pipeline of product candidates for both large market and rare diseases, including patient populations that other genetic medicines are unable to address. The firm's initial product candidates are focused on therapeutic areas, such as ophthalmology, pulmonology, and cardiology. The firm's five product candidates include 4D-150, 4D-710, 4D-125, 4D-110, and 4D-310. 4D-150 is used for the treatment of wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME). 4D-710 is used for the treatment of cystic fibrosis lung disease (both in modulator ineligible and eligible populations). 4D-310 is used for the treatment of Fabry disease cardiomyopathy. 4D-125 for the treatment of X-linked retinitis pigmentosa (XLRP). 4D-110 is used for the treatment of choroideremia.